Generics the winners in Chinese regulatory overhaul?
This article was originally published in SRA
Executive Summary
As debate continues over Chinese President Xi Jinping's true commitment to meaningful reforms, sweeping draft revisions to drug registration regulations laid out by the China Food and Drug Administration earlier this month1,2 show parts of the bureaucracy are already forging ahead.